Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365287 | 1.00 | ELANE (0.43) | ELANEMAPTCTSGCMA1PPARG | |
| SCHEMBL6372971 | 0.93 | ELANE (0.47) | ELANEMAPTPPARGPPARAACE | |
| SCHEMBL6372963 | 0.93 | ELANE (0.47) | ELANEMAPTPPARGPPARAACE | |
| SCHEMBL6366813 | 0.92 | ACE (0.43) | ELANEPPARGPPARAACEPTPN1 | |
| SCHEMBL6366808 | 0.92 | ACE (0.43) | ELANEPPARGPPARAACEPTPN1 | |
| SCHEMBL6364946 | 0.87 | ELANE (0.43) | ELANEMAPTPPARGPPARAACE | |
| SCHEMBL6365736 | 0.86 | HDAC4 (0.46) | ELANE | |
| SCHEMBL6365727 | 0.86 | HDAC4 (0.46) | ELANE | |
| SCHEMBL6365249 | 0.85 | ACE (0.48) | ELANEPPARGPPARAACEPTPN1 | |
| SCHEMBL6365244 | 0.85 | ACE (0.48) | ELANEPPARGPPARAACEPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272784-A1 | Inhibitors of bacterial Type III protein secretion systems | LI XIAOBING | 2005-12-08 | — | — | US | disclosed |
| WO-2005113522-A1 | AZOLE CARBOXAMIDE INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272784-A1 | Inhibitors of bacterial Type III protein secretion systems | GBA3, PSMB3, SEC61B | ELANE 117/4885MAPT 4549/4885CTSG 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.